Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Residual homing of α4β7-expressing β1 + PI16 + regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumab

30 Aug 2021

Abstract excerpt

Objective The anti-α4β7 integrin antibody vedolizumab is administered at a fixed dose for the treatment of IBDs. This leads to a wide range of serum concentrations in patients and previous studies had suggested that highest exposure levels are associated with suboptimal clinical response. We aimed to determine the mechanisms underlying these non-linear exposure-efficacy characteristics of vedolizumab. Design We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Adhesion Molecules Research
Share to Single-cell and spatial transcriptomics
Share to T-cell and B-cell Immunology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34462337
DOI: 10.1136/gutjnl-2021-324868

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Residual homing of α4β7-expressing β1 + PI16 + regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumabPMID 34462337Read ↗

Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease.Semantic proximity Read ↗

Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease.Semantic proximity Read ↗

Multimodal Profiling of Peripheral Blood Identifies Proliferating Circulating Effector CD4+ T Cells as Predictors for Response to Integrin α4β7-Blocking Therapy in Inflammatory Bowel Disease.Semantic proximity Read ↗

Gut-associated lymphoid tissue attrition associates with response to anti-α4β7 therapy in ulcerative colitisSemantic proximity Read ↗

High-dimensional single-cell analysis identifies cellular signatures associated with response to vedolizumab therapy in ulcerative colitisSemantic proximity Read ↗

Downregulated Interferon Signalling in T Cells is Associated with Response to Vedolizumab in Inflammatory Bowel DiseaseSemantic proximity Read ↗

A mutation that blocks integrin α4β7 activation prevents adaptive immune-mediated colitis without increasing susceptibility to innate colitis.Semantic proximity Read ↗

Integrin α4β7 Blockade Preferentially Impacts CCR6+ Lymphocyte Subsets in Blood and Mucosal Tissues of Naive Rhesus MacaquesSemantic proximity Read ↗

Regulation and Role of αE Integrin and Gut Homing Integrins in Migration and Retention of Intestinal Lymphocytes during Inflammatory Bowel DiseaseSemantic proximity Read ↗

Aberrant activation of integrin alpha4beta7 suppresses lymphocyte migration to the gut.Semantic proximity Read ↗

Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn's Disease.Semantic proximity Read ↗

Small-Molecule Antagonist of VLA-4 (GW559090) Attenuated Neuro-Inflammation by Targeting Th17 Cell Trafficking across the Blood-Retinal Barrier in Experimental Autoimmune UveitisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.